[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621763":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":96,"collaborators":98,"id":101,"slug":102,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":19,"eligibilityCriteria":107,"healthyVolunteers":103,"sex":108,"minAge":109,"maxAge":19,"enrollmentInfo":110,"targetDuration":19,"studyType":113,"phases":114,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":135},{"fullName":5,"class":6},"Zai Lab (Hong Kong), Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ZL-6201","EXPERIMENTAL","ZL-6201 as a single agent",[13],"Drug: ZL-6201",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","ZL-6201 as a single-agent",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"ZL-6201-001 Study Team","CONTACT","(510)-316-3502","ZL-6201-001@zailaboratory.com",[27,41,51,64,74,83],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":19},"Zai Lab Site 02003","RECRUITING","Los Angeles","California","90007","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-118.24368,34.05223,{"lat":39,"lon":38},{"facility":42,"status":29,"city":43,"state":44,"zip":45,"country":33,"countryCode":34,"cosmosGeoPoint":46,"geoPoint":50,"contacts":19},"Zai Lab Site 02030","New Haven","Connecticut","06510",{"type":36,"coordinates":47},[48,49],-72.92816,41.30815,{"lat":49,"lon":48},{"facility":52,"status":29,"city":53,"state":54,"zip":55,"country":33,"countryCode":34,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Zai Lab Site 02026","Sarasota","Florida","34232",{"type":36,"coordinates":57},[58,59],-82.53065,27.33643,{"lat":59,"lon":58},[62],{"name":63,"role":23,"phone":19,"phoneExt":19,"email":19},"Site 02026",{"facility":65,"status":29,"city":66,"state":67,"zip":68,"country":33,"countryCode":34,"cosmosGeoPoint":69,"geoPoint":73,"contacts":19},"Zai Lab Site 02005","St Louis","Missouri","63160",{"type":36,"coordinates":70},[71,72],-90.19789,38.62727,{"lat":72,"lon":71},{"facility":75,"status":29,"city":76,"state":76,"zip":77,"country":33,"countryCode":34,"cosmosGeoPoint":78,"geoPoint":82,"contacts":19},"Zai Lab Site 02002","New York","10065",{"type":36,"coordinates":79},[80,81],-74.00597,40.71427,{"lat":81,"lon":80},{"facility":84,"status":29,"city":85,"state":86,"zip":87,"country":33,"countryCode":34,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"Zai Lab Site 02006","Fairfax","Virginia","22031",{"type":36,"coordinates":89},[90,91],-77.30637,38.84622,{"lat":91,"lon":90},[94],{"name":95,"role":23,"phone":19,"phoneExt":19,"email":19},"Site 02006",{"type":97,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[99],{"name":100,"class":6},"Zai Lab (US) LLC","100621763","phase-1-phase-1ab-study-of-zl-6201-safety-pk-and-preliminary-efficacy-in-sarcoma-and-selected-tumors-100621763",false,"NCT07374848","Phase 1a\u002Fb Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors","An Open-label, Phase 1a\u002Fb, Multicenter Study of ZL-6201 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy in Participants With Sarcoma and Selected Solid Tumors","Inclusion Criteria:\n\n* Adult men and women ≥18 years of age at the time of signing the ICF with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and a life expectancy \\> 3 months\n* Participants must have histologically confirmed and documented diagnosis of locally advanced unresectable and\u002For metastatic sarcoma or a selected solid tumor\n* Participants must be willing to undergo a tumor biopsy prior to start of treatment or provide archived tumor tissue sample\n* Participants with sarcoma should have received no more than 2 lines of previous systemic therapies in the metastatic setting\n* Participants with selected epithelial solid tumors should have received no more than 3 lines of previous systemic therapy in the metastatic\u002Frelapsed refractory setting\n* Participants must have at least one measurable target lesion as defined by RECIST v1.1\n* Adequate organ and marrow function as listed per protocol\n* Must be negative for HIV, HBV, and HCV\n\nExclusion Criteria:\n\n* Participants with another known malignancy that has required treatment within the last 2 years\n* Symptomatic central nervous system (CNS) metastasis, and\u002For those requiring therapy with corticosteroids or anticonvulsants to control associated symptoms\n* Participants with leptomeningeal metastasis\n* Most recent systemic anti-cancer treatment or investigational products\u002Fdevices less than 3 weeks\n* Prior treatment with a topoisomerase-1 inhibitor antibody drug conjugate\n* Impaired cardiac function or clinically significant cardiac disease within the last 3 months before administration of the first dose of the study treatment\n* Clinically significant pulmonary disease including autoimmune, connective tissue, or inflammatory conditions\n* Pregnant or nursing (lactating) women","ALL","18 Years",{"count":111,"type":112},180,"ESTIMATED","INTERVENTIONAL",[115],"PHASE1","The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.",[118,119],"Solid Tumors","Sarcomas",[121,118,122,123,124],"Sarcoma","Phase1","Antibody-Drug Conjugate (ADC)","Leucine-Rich Repeat-Containing protein 15 (LRRC15)","2026-06-18",{"date":127,"type":128},"2026-06-22","ACTUAL",{"date":130,"type":128},"2026-03-02",{"date":132,"type":112},"2029-09",{"name":134,"class":6},"Zai Lab (Shanghai) Co., Ltd.",6]